Yonsu Son

1.2k total citations
49 papers, 712 citations indexed

About

Yonsu Son is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Yonsu Son has authored 49 papers receiving a total of 712 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Rheumatology, 22 papers in Immunology and 12 papers in Hematology. Recurrent topics in Yonsu Son's work include Rheumatoid Arthritis Research and Therapies (23 papers), Systemic Lupus Erythematosus Research (19 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Yonsu Son is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (23 papers), Systemic Lupus Erythematosus Research (19 papers) and Autoimmune and Inflammatory Disorders Research (11 papers). Yonsu Son collaborates with scholars based in Japan, United States and Vietnam. Yonsu Son's co-authors include Hideki Amuro, Yoshio Ozaki, Tomoki� Ito, Shosaku� Nomura, Akihiro Tanaka, Keiko Shimamoto, Motomu Hashimoto, Masaki Katayama, Ryota Hara and Kosuke Ebina and has published in prestigious journals such as PLoS ONE, Biochemical and Biophysical Research Communications and International Journal of Molecular Sciences.

In The Last Decade

Yonsu Son

47 papers receiving 703 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yonsu Son Japan	16	412	264	162	104	80	49	712
R Fleischmann United States	8	375 0.9×	213 0.8×	187 1.2×	79 0.8×	90 1.1×	29	674
Ceara AE Walsh Ireland	10	394 1.0×	198 0.8×	158 1.0×	85 0.8×	82 1.0×	11	717
Žiga Rotar Slovenia	18	547 1.3×	168 0.6×	125 0.8×	147 1.4×	79 1.0×	75	850
Ettore Silvagni Italy	17	579 1.4×	269 1.0×	125 0.8×	54 0.5×	92 1.1×	49	816
Antonio Sánchez United States	6	680 1.7×	249 0.9×	342 2.1×	152 1.5×	66 0.8×	20	1.0k
Ed Keystone Canada	11	365 0.9×	147 0.6×	144 0.9×	97 0.9×	98 1.2×	25	572
Regina Kurrasch United States	12	266 0.6×	188 0.7×	71 0.4×	77 0.7×	59 0.7×	21	534
Claudio Galarza-Maldonado Mexico	14	396 1.0×	177 0.7×	144 0.9×	41 0.4×	46 0.6×	24	594
S. Marzouk Tunisia	14	327 0.8×	255 1.0×	61 0.4×	41 0.4×	129 1.6×	94	652
M. C. Genovese United States	10	634 1.5×	228 0.9×	320 2.0×	162 1.6×	53 0.7×	38	842

Countries citing papers authored by Yonsu Son

Since Specialization

Citations

This map shows the geographic impact of Yonsu Son's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yonsu Son with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yonsu Son more than expected).

Fields of papers citing papers by Yonsu Son

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yonsu Son. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yonsu Son. The network helps show where Yonsu Son may publish in the future.

Co-authorship network of co-authors of Yonsu Son

This figure shows the co-authorship network connecting the top 25 collaborators of Yonsu Son. A scholar is included among the top collaborators of Yonsu Son based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yonsu Son. Yonsu Son is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ōnishi, Akira, Koichi Murata, Kosaku Murakami, et al.. (2025). Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study. Arthritis Research & Therapy. 27(1). 52–52. 3 indexed citations

Nakayama, Yoichi, Ryu Watanabe, Wataru Yamamoto, et al.. (2023). IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study. Lara D. Veeken. 63(2). 349–357. 5 indexed citations

Ōnishi, Akira, Wataru Yamamoto, Ryu Watanabe, et al.. (2023). Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis. Lara D. Veeken. 63(11). 3065–3073. 3 indexed citations

Shiba, Hideyuki, Takuya Kotani, Koji Nagai, et al.. (2023). Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study. International Journal of Molecular Sciences. 24(8). 7399–7399. 4 indexed citations

Etani, Yuki, Kosuke Ebina, Yasutaka Okita, et al.. (2023). AB0407 IMPACT OF SEROPOSITIVITY ON DRUG RETENTION OF BIOLOGICS AND JAK INHIBITORS -THE ANSWER COHORT STUDY. Annals of the Rheumatic Diseases. 82. 1389–1389. 1 indexed citations

Yamazaki, Fumikazu, Akihiro Tanaka, Yonsu Son, et al.. (2023). The Correlation between the Vascular Calcification Score of the Coronary Artery and the Abdominal Aorta in Patients with Psoriasis. Diagnostics. 13(2). 274–274. 1 indexed citations

Ebina, Kosuke, Tôru Hirano, Yuichi Maeda, et al.. (2021). Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clinical Rheumatology. 40(7). 2673–2680. 16 indexed citations

Jinno, Sadao, Akira Ōnishi, Maureen Dubreuil, et al.. (2021). Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study. Arthritis Research & Therapy. 23(1). 116–116. 12 indexed citations

Maeda, Yuichi, Tôru Hirano, Kosuke Ebina, et al.. (2021). Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study. Rheumatology International. 41(7). 1233–1241. 1 indexed citations

10.

Maeda, Yuichi, Tôru Hirano, Ryota Hara, et al.. (2020). THU0174 ANTI-IL-6 RECEPTOR ANTIBODY AMELIORATES DISEASE ACTIVITY OF RHEUMATOID ARTHRITIS PATIENTS WITH KNEE JOINT INVOLVEMENT -ANSWER COHORT STUDY-. Annals of the Rheumatic Diseases. 79. 302–303. 1 indexed citations

11.

Ebina, Kosuke, Tôru Hirano, Yuichi Maeda, et al.. (2020). Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-. Clinical Rheumatology. 39(9). 2563–2572. 14 indexed citations

12.

Jinno, Sadao, Akira Ōnishi, Maureen Dubreuil, et al.. (2020). Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatology International. 40(12). 1987–1995. 15 indexed citations

13.

Murata, Koichi, Motomu Hashimoto, Wataru Yamamoto, et al.. (2019). The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. Rheumatology International. 40(2). 217–225. 6 indexed citations

14.

Ebina, Kosuke, Motomu Hashimoto, Wataru Yamamoto, et al.. (2019). Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. Arthritis Research & Therapy. 21(1). 91–91. 39 indexed citations

15.

Hashimoto, Motomu, Moritoshi Furu, Ryota Hara, et al.. (2018). Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Research & Therapy. 20(1). 165–165. 21 indexed citations

16.

Shimamoto, Keiko, Tomoki� Ito, Yoshio Ozaki, et al.. (2013). Serum Interleukin 6 Before and After Therapy with Tocilizumab Is a Principal Biomarker in Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 40(7). 1074–1081. 83 indexed citations

17.

Ozaki, Yoshio, Akihiro Tanaka, Keiko Shimamoto, et al.. (2012). Effective intravenous immunoglobulin therapy for Churg-Strauss syndrome (allergic granulomatous angiitis) complicated by neuropathy of the eighth cranial nerve: a case report. Journal of Medical Case Reports. 6(1). 310–310. 4 indexed citations

18.

Ozaki, Yoshio, Akihiro Tanaka, Keiko Shimamoto, et al.. (2010). A case of rheumatoid pericarditis associated with a high IL-6 titer in the pericardial fluid and tocilizumab treatment. Modern Rheumatology. 21(3). 302–304. 12 indexed citations

19.

Yokoi, Takashi, Ryuichi Amakawa, H. Sugimoto, et al.. (2008). Mycobacterium bovis Bacillus Calmette-Guerin suppresses inflammatory Th2 responses by inducing functional alteration of TSLP-activated dendritic cells. International Immunology. 20(10). 1321–1329. 19 indexed citations

20.

Nakamura, Yoshio, Yonsu Son, Dai Shimono, et al.. (2001). Case of Adrenocorticotropic Hormone-Independent. Endocrine. 15(1). 57–62. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact